[OncoTargets and Therapy] In this review, researchers summarize use, indications, and clinical safety and efficacy of olaparib, a PARP inhibitor, in the treatment of ovarian cancer, including in patients with BRCA mutations.
Some experts say the talc study’s data limitations weaken its impact in the field.
This study found that many rural-living patients with colorectal or cervical cancer may have to travel significantly greater distances to reach a cancer specialist than urban dwellers.
Screening rates are insufficient to reduce cervical cancer incidence.
In this study, researchers identified 8 common themes related to challenges patients experience with ostomy self-management.